Skip to main content
Equibles
SLN logo

SLN · Silence Therapeutics plc

Track SLN — free

Use SLN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SLN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$13.02 -0.29 (-2.18%) At close · Sep 11
Rebalance outlook locked
Market Cap
$809.25M
Shares
62.15M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$13.02 Open$13.32 Day$12.88–13.42 52W close$4.30–15.43 Avg vol 30d1.5M Short int2.4M · 3.9% float · 3.5d Short vol36% Last earningsFeb 27, 2025 DataSep 2020–Sep 2026 Filing10-Q · Aug 10

Up next

Latest filing: 10-Q
filed Aug 10, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.0%
Year over year · more shares
Price change (1Y)
+176.7%
Trailing year
Short interest
3.9%
Latest settlement · 3.5 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +67%
above
Price vs 50-day avg +6%
above
RSI (14) 47
neutral
MACD trend Negative
52-week position 78%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −7%
trailing
6-month return +111%
trailing
YTD return +114%
this year
Relative strength +93%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $12 › 200d $8 — 50d above 200d
Institutional flow Accumulating
+29% holders QoQ · +20 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
3.92% of float · ▲ +0.1% MoM · 3.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
72 holders — near 3-yr high, broad support
Squeeze score 50
elevated · 0–100
Fundamentals
Weak
Revenue growth −99%
Y/Y
Gross margin 62%
contracting
EPS growth −91%
Y/Y
Free cash flow $-62.3M
Quant / Vol
risk profile
Very High
Volatility 85%
annualized · 1-yr
Max drawdown −42%
past year
ATR 6.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+67% Bullish
Price vs 50-day avg
+6% Bullish
RSI (14)
47 Neutral
MACD trend
Negative Bearish
52-week position
78% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $12 › 200d $8 — 50d above 200d
Institutional flow Accumulating
+29% holders QoQ · +20 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
3.92% of float · ▲ +0.1% MoM · 3.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
72 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $4 Now $13 · 78% Range high $15
vs 200-day avg +67% vs 50-day avg +6%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SLN
Silence Therapeutics plc
this stock
$809.25M +114.1% -98.7% — 3.9%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.60B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
72
% held
36.8%
Net QoQ
+2.9M sh
Top holder
Siren, L.L.C.
Held Float
View
Held by Funds
Fund positions
9
View
Short & Settlement
Short Interest Rising
Shares short
2.4M
Days to cover
3.5d
Change
+3.0K sh
View
Short Volume
Short vol %
36%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
3.8K
Value
$58.9K
As of
Aug 11, 2026
View
Off-Exchange
Off-exchange %
47.2%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$559.0K
Net income (FY)
$-88.6M
EPS diluted
$-0.63
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 12, 2026
This year
16
View
Exempt Offerings
Offering
$45.5M
Filed
Feb 18, 2021
View
Earnings & Events
Earnings Calls
Last call
Jun 3, 2026
View
Investor Relations
Latest news
Silence Therapeutics Highlights F…
Published
Jun 11, 2026
View

Performance

5D 20D 120D MTD YTD
SLN -12.0% -6.8% +111.0% -3.8% +114.1%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -10.8% -5.1% +93.2% -3.4% +102.1%
Key facts CIK 1479615 CUSIP 82686Q101 13F (30d) 51 filings 51 filers Visit website Investor relations